Regentis Biomaterials Reports Strong Surgeon Interest in GelrinC(R) at 8th ICRS Summit in PortugalAccesswire · Oct 12, 2026
Regentis Biomaterials to Present at the 2026 ThinkEquity Conference on October 15 in New York CityAccesswire · Oct 9, 2026
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials Ltd.GlobeNewsWire · Sep 18, 2026
Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate UpdateAccesswire · Sep 11, 2026Regentis Biomaterials Ltd. is a regenerative medicine firm dedicated to crafting innovative solutions for tissue repair, ultimately aiming to enhance patients' health and overall quality of life. The company's primary product in development is GelrinC, a novel, cell-free, ready-to-use hydrogel designed to be solidified into an implant within the knee. This implant serves to address painful knee injuries and mend articular cartilage damage.